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S U M M A R Y
Disseminated Nocardia veterana infection has rarely been reported. We describe the ﬁrst reported case of
N. veterana bacteremic pneumonia in an HIV-infected patient. The isolate was conﬁrmed by 16S rRNA
sequencing analysis. The patient initially responded well to trimethoprim–sulfamethoxazole treatment
(minimum inhibitory concentration 0.25 mg/ml), but died of ventilator-associated pneumonia.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Infections caused by Nocardia species have been increasing
because of the growing population of immunocompromised hosts.
Clinical manifestations of nocardiosis range from cutaneous
infections in normal hosts to severe pulmonary and central
nervous systemdiseases in immunocompromised hosts.1 Themost
common predisposing factors for opportunistic Nocardia infec-
tions are long-term steroid use, neoplastic disease, and HIV
infection.1 Due to improvements in the identiﬁcation of Nocardia
species in the clinical laboratory, the genus Nocardia is rapidly
expanding, with at least 80 species described to date (http://
www.bacterio.cict.fr/n/nocardia.html). Identiﬁcation of clinical
isolates beyond the genus level is important, since strains of
Nocardia species differ in the clinical spectrum of the disease they
cause and their susceptibility to antibiotics.1 Nocardia cyriacigeor-
gica, Nocardia nova, and Nocardia brasiliensis are the most
commonly encountered species in human infections.1–5 In
contrast, Nocardia veterana, a newly identiﬁed species, was ﬁrst
isolated from a 78-year-old man with a history of tuberculous
pleurisy, but the strain was not considered to be clinically* Corresponding author.
E-mail address: hsporen@ntu.edu.tw (P.-R. Hsueh).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.03.001signiﬁcant.2 We describe herein the ﬁrst reported case of N.
veterana bacteremic pneumonia in an HIV-infected patient.
2. Case report
A 30-year-old man presented with productive cough and
progressive dyspnea for 1 week. He had had one episode of
moderate hemoptysis 2 days prior to visiting the hospital. His
medical history included HIV infection without highly active
antiretroviral treatment (HAART) for 2 years, old tuberculosis with
complete anti-tuberculosis treatment, and chronic hepatitis B with
positive hepatitis B surface antigen. He had been unemployed for
the 10 months prior to admission.
The patient reported no headache, chest pain, vomiting,
diarrhea, night sweats, chills, or myalgia. His body weight was
45 kg and body height was 178 cm. Physical examination revealed
a temperature (ear) of 36.6 8C, pulse rate of 120 beats/min,
respiratory rate of 32/min, blood pressure of 105/43 mmHg, and
pulse oximeter saturation of 81% under ambient air. Coarse
crackles were heard over both lung ﬁelds, especially the right
upper lung. No heart murmur was audible. There was no
lymphadenopathy or hepatosplenomegaly. Laboratory data
revealed a white blood cell count of 15.31  109/l with neutrophil
predominance (96%), hemoglobin of 10.9 mg/dl, serum urea
nitrogen of 61 mg/dl, serum creatinine of 1.4 mg/dl, alanineses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Chest radiograph shows patchy consolidation over the right upper lung
(arrow) and diffuse inﬁltration over bilateral lung ﬁelds (arrow head).
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2.31 g/dl, lactate dehydrogenase of 623 U/l (reference value <460
U/l), sodium of 149 mmol/l, and C-reactive protein of 18.52 mg/dl
(reference value <0.8 mg/dl). Arterial blood gas analysis under
oxygen use with a non-rebreathingmask (FiO2 of 98%) revealed pH
7.43, PCO2 52.2 mmHg, HCO3
 33.9 mEq/l, and PO2 92 mmHg.
There was no pyuria or hematuria. The CD4 count was 3/ml (1%);
his HIV viral load was 29 500 copies/ml.
Chest radiography on admission revealed diffuse inﬁltration
over bilateral lung ﬁelds and patchy consolidation over the right
upper lung (Figure 1). The patientwas intubated due to hypoxemic
respiratory failure and was admitted to the intensive care unit.
Testing for Chlamydia pneumoniae antigen (bioMe´rieux, Marcy-
l’Etoile, France) was negative. Serological testing for anti-Myco-
plasma pneumoniae IgM (Savyon Diagnostics Ltd, Ashdod, Israel)
was negative. The inﬂuenza rapid test (QuickVue Inﬂuenza A+B
test, bioMe´rieux, San Diego, CA, USA) of a nasopharyngeal swab
sample and Legionella urinary antigen test for serogroup 1 (Binax
Inc., Portland, ME, USA) were both negative, but a Binax NOW
Streptococcus pneumoniae urinary antigen test (Binax Inc.) was
positive.
Three sets of blood cultures and one set of sputum cultures
were performed. Empirical antibiotic therapy with moxiﬂoxacin
(400 mg every day) and clarithromycin (500 mg every 12 h) was
started to cover the probable infection due to S. pneumoniae and
atypical pathogens. Intravenous trimethoprim–sulfamethoxazole
(800 mg/160 mg every 8 h) was administered because of the
possibility of Pneumocystis jirovecii pneumonia (PJP). Bronchoal-
veolar lavage (BAL) from the right upper bronchial tree and a
transbronchial lung biopsy from the lesions over the left lower lobe
were performed on the third hospital day. Pathological examina-
tion of lung biopsy tissue using Gomori’s methenamine silver stain
revealed clusters of cysts within the alveolar space suggesting P.
jirovecii, however there was no evidence of concomitant cytomeg-
alovirus infection. The patient had not received trimethoprim–
sulfamethoxazole prophylaxis before.
Many branching and ﬁlamentous Gram-positive and weakly
acid-fast positive bacteria were found in the BAL ﬂuid, while P.jirovecii was found using Giemsa stain (Muto Pure Chemicals Ltd,
Tokyo, Japan). Bacterial, mycobacterial and fungal cultures of the
BAL ﬂuid were negative. Three sets of blood cultures using the
Bactec 9240 automated culturing system in Aerobic/F bottles with
resin (BD Diagnostic System, Sparks, MD, USA) all grew branching
Gram-positive bacteria after incubation for 5 days. Using a
modiﬁed acid-fast stain the isolates were also weakly acid-fast
bacteria, suggesting the presence of Nocardia species.
The dosage of trimethoprim–sulfamethoxazole was therefore
increased to 1600 mg/320 mg every 8 h for the treatment of PJP
and disseminated Nocardia infection (pneumonia and bacter-
emia). The patient’s clinical condition, including dyspnea,
oxygenation and lung inﬁltration on chest radiography, all
gradually improved. Seven days later, repeat blood cultures
were performed and yielded no growth. However, one episode of
ventilator-associated pneumonia caused by Acinetobacter bau-
mannii occurred 10 days after admission, and moxiﬂoxacin and
clarithromycin were changed to imipenem according to the
culture results. The patient’s condition deteriorated and multi-
ple-organ failure developed. The patient died 1 month after
hospital admission.
2.1. Microbiology
The Nocardia isolates were branching, beaded, ﬁlamentous
Gram-positive bacilli and were weakly positive with acid-fast
stain. The isolate grew well on blood agar plate and had negative
reactions for hydrolysis of casein, xanthine, hypoxanthine, and
tyrosine. The isolate was further conﬁrmed to the species level by
16S rRNA gene analysis. Partial sequencing analysis of the 16S
rRNA gene was performed using the primers Noc1 (50-GCTTAA-
CACATGCAAGTCG-30; positions 46 to 64, Escherichia coli number-
ing system) and Noc2 (50-GAATTCCAGTCTCCCCTG-30; positions
663 to 680, E. coli numbering system). The sequences were
comparedwith published sequences in the 16S rRNA database. The
sequences obtained (823 bp) were compared with published
sequences in the GenBank database using the BLASTN algorithm
(http://www.ncbi.nlm.nih.gov/blast). The closest match was
obtained with N. veterana (GenBank accession No. GQ376181;
maximal score 1507, E value 0.0, and maximal identity 99% (821/
823)). The isolate had a positive reaction for urea hydrolysis and
positive growth at 45 8C, which were compatible with the
identiﬁcation of N. veterana (not Nocardia africana or N. nova).2–4
The minimum inhibitory concentrations (MICs) of trimethoprim–
sulfamethoxazole, ciproﬂoxacin, clarithromycin, and imipenem
were 0.25, >32, 0.03, and 0.12mg/ml, respectively, as determined
by the broth microdilution method.1
3. Discussion
N. veterana is an opportunistic pathogen in humans that can
cause respiratory tract infection, primary cutaneous infection, and
peritonitis.2–4 Bloodstream infection due to N. veterana is a rare
condition, which has only been reported once in the literature in a
patient with chronic lymphocytic leukemia and lung cancer. The
condition resolved without further sequelae after antibiotic
treatment.5
The present case is the ﬁrst report of concomitant PJP and N.
veterana bacteremic pneumonia in an HIV-infected patient. In
addition to the present case, another previous report has described
a cancer patient with N. veterana bacteremia complicating a
pulmonary infection; the patient recovered completely after 3
weeks of antibiotic treatment that included trimethoprim–
sulfamethoxazole.5 N. veterana, which was probably secondary
to the pulmonary infection, was isolated in pure culture three
times from the blood of this immunocompromised patient over the
W.-L. Liu et al. / International Journal of Infectious Diseases 15 (2011) e430–e432e432course of 2 days. The identiﬁcation ofN. veteranawas conﬁrmed by
molecular methods in addition to conventional biochemical
studies. The untreated HIV infection should be considered the
main predisposing factor for N. veterana bacteremia in the present
case.
Trimethoprim–sulfamethoxazole has good in vitro activity
against N. brasiliensis and N. asteroides, but its activity against
other Nocardia species varies.1 Based on limited in vitro studies
of antimicrobial agents against N. veterana, most reported
clinical isolates have been susceptible to trimethoprim–sulfa-
methoxazole.5 Our patient initially responded well to treatment
with trimethoprim–sulfamethoxazole, which showed fair in
vitro activity against the isolate (MIC of 0.25 mg/ml). In addition,
previous studies have shown the MIC ranges of imipenem for six
clinical isolates to be as low as 0.032 to 1 mg/ml.3–5 However,
further in vitro and in vivo studies are needed to deﬁne the
appropriate management for N. veterana infection. Although
most reported cases of N. veterana infection have had various
immunocompromising conditions, including transplantation,
systemic lupus erythematosus, cancer, HIV infection and steroid
use, a fatal outcome has rarely been reported.4 Death occurredbefore antibiotic treatment started in only one case of N.
veterana peritonitis in an HIV-infected patient.4
In conclusion, N. veterana can cause disseminated infection in
patients of immunocompromised status, such as thosewith an HIV
infection. Sequencing of the 16S rRNA gene is crucial for the
accurate identiﬁcation of this emerging pathogen.
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